Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Semaglutide is approved for the treatment of obesity in a subcutaneous formulation at a dose of 2.4 mg OW
Some notice mild nausea during the first 2 to 3 days after the initial injection
Dehydration from gastrointestinal side effects may also play a role
Serious Health Risks: When to Wave the Red Flag While most side effects are manageable annoyances, some require immediate attention
Serious side effects are rare but worth knowing about
of patients using Semaglutide & Tirzepatide reported significant weight loss in the first 3 months
US$ 21.02
US$ 29.53
.jpg)
)
US$ 21.12
)
